Oragenics Inc. (OGEN)
Stock Price:
$0.520 USD
-0.010 (-1.94%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed
After-hours: $0.516 -0.004 (-0.77%) Oct 28, 8:00 PM
Key Info
| Market Cap |
31.72M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-24.96M |
| Shares Out |
61.00M |
| EPS (ttm) |
-0.52 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$0.520 |
| Previous Close |
$0.530 |
| Change ($) |
-0.010 |
| Change (%) |
-1.94% |
| Day's Open |
0.529 |
| Day's Range |
0.501 - 0.529 |
| Day's Volume |
855,173 |
| 52-Week Range |
0.360 - 2.090 |
More Stats
| Market Cap |
31.72M |
| Enterprise Value |
22.98M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
61.00M |
| Float |
49.45M |
| EPS (basic) |
-0.51 |
| EPS (diluted) |
-0.52 |
| FCF / Share |
-0.31 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.33M |
| Short Ratio |
0.44 |
| Short % of Float |
2.69% |
| Beta |
0.53 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
20.46 |
| Revenue |
n/a |
| Operating Income |
-25.16M |
| Net Income |
-24.96M |
| Free Cash Flow |
-15.98M |
| Net Cash |
8.74M |
| Net Cash / Share |
0.14 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-83.52% |
| ROE |
-150.31% |
| ROIC |
-7,526.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
2.50
Current: $0.520
High
2.50
Target: 2.50
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | 0.94 | 1.03 | 1.33 | 1.44 | 1.31 |
| Revenue Growth | - | - | - | - | - | -8.94% | -22.49% | -7.8% | 10.35% | - |
| Gross Profit | - | - | - | - | - | 0.57 | 0.69 | 0.45 | 0.73 | 0.40 |
| Operating Income | -15.88 | -9.99 | -6.72 | -8.54 | -11.78 | -5.82 | -16.21 | -12.43 | -7.35 | -7.90 |
| Net Income | -15.57 | -9.91 | -6.73 | -7.01 | -11.71 | -5.79 | -16.07 | -13.09 | -7.68 | -7.81 |
| Shares Outstanding | 42.28 | 13.04 | 4.93 | 4.46 | 3.67 | 3.62 | 2.88 | 1.77 | 0.57 | 0.55 |
| Earnings Per Share | -0.37 | -0.87 | -1.37 | -1.57 | -3.20 | -1.60 | -5.60 | -7.40 | -13.40 | -14.20 |
| Operating Cash Flow | -13.01 | -9.08 | -6.36 | -7.08 | -5.19 | -5.56 | -6.76 | -5.21 | -5.49 | -6.45 |
| Capital Expenditures | -0.03 | -0.12 | - | -0.02 | -0.10 | -0.11 | -0.02 | -0.01 | - | -0.09 |
| Free Cash Flow | -13.04 | -9.20 | -6.36 | -7.10 | -5.29 | -5.67 | -6.78 | -5.22 | -5.49 | -6.54 |
| Cash & Equivalents | 18.27 | 20.21 | 6.17 | 4.08 | 5.08 | 10.45 | 16.28 | 9.99 | 0.44 | 0.61 |
| Total Debt | 0.98 | 0.12 | 0.08 | 0.07 | 0.06 | 0.06 | 0.06 | 0.05 | 7.55 | 2.10 |
| Net Cash / Debt | 17.29 | 20.08 | 6.09 | 4.01 | 5.02 | 10.38 | 16.21 | 9.94 | -7.12 | -1.49 |
| Assets | 19.75 | 22.05 | 7.21 | 4.31 | 5.78 | 11.13 | 16.83 | 10.49 | 1.27 | 1.73 |
| Liabilities | 2.52 | 1.17 | 0.90 | 1.34 | 1.05 | 0.80 | 0.99 | 1.26 | 9.45 | 3.63 |
| Book Value | 17.23 | 20.88 | 6.32 | 2.97 | 4.73 | 10.34 | 15.84 | 9.23 | -8.18 | -1.90 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Oragenics Inc. |
| Country |
United States |
| Employees |
7 |
| CEO |
Alan F. Joslyn |
Stock Information
| Ticker Symbol |
OGEN |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSEAMERICAN: OGEN |
Description
Oragenics develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring compound for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against dental caries, or tooth decay. Oragenics, Inc. has collaboration agreements with Precigen, Inc. and its subsidiary, Intrexon Actobiotics NV to develop AG013; and a license agreement with LPThera LLC to develop LPT3-04. It also has a process development and drug substance manufacturing agreement with Avid Bioservices, Inc. for coronavirus vaccine. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.